Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF KRESTIN AS ADJUVANT TREATMENT FOLLOWING RADICAL RADIOTHERAPY IN NONSMALL CELL LUNG-CANCER PATIENTS
Autore:
HAYAKAWA K; MITSUHASHI N; SAITO Y; NAKAYAMA Y; FURUTA M; NAKAMOTO S; KAWASHIMA M; NIIBE H;
Indirizzi:
GUNMA UNIV,SCH MED,DEPT RADIOL & RADIAT ONCOL,3-39-22 SHOWA MACHI MAEBASHI GUMMA 371 JAPAN
Titolo Testata:
Cancer detection and prevention
fascicolo: 1, volume: 21, anno: 1997,
pagine: 71 - 77
SICI:
0361-090X(1997)21:1<71:EOKAAT>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
RADIATION-THERAPY; RANDOMIZED TRIAL; STAGE-I; TUMOR-CONTROL; PSK; CHEMOTHERAPY; CARCINOMA; IRRADIATION; INDUCTION; SURVIVAL;
Keywords:
NONSMALL CELL LUNG CANCER; SQUAMOUS CELL CARCINOMA OF THE LUNG; RADIOTHERAPY; BIOTHERAPY; ADJUVANT IMMUNOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
28
Recensione:
Indirizzi per estratti:
Citazione:
K. Hayakawa et al., "EFFECT OF KRESTIN AS ADJUVANT TREATMENT FOLLOWING RADICAL RADIOTHERAPY IN NONSMALL CELL LUNG-CANCER PATIENTS", Cancer detection and prevention, 21(1), 1997, pp. 71-77

Abstract

To evaluate the efficacy of Krestin (PSK) as adjuvant treatment afterradical radiation therapy (RT) for non-small cell lung cancer (NSCLC), treatment results of 225 patients with NSCLC treated with RT followed by adjuvant administration of PSK between 1976 and 1989 were analyzed. Of these patients, 170 (76%) had squamous cell carcinoma. In the patients with squamous cell carcinoma of the lung, PSK was given only when the tumor showed satisfactory shrinkage (complete or partial response) after completion of RT. The treatment outcomes were compared with those of the responders to RT not receiving PSK. The 5-year survival rates of patients with stages I-II and stage III disease were 39 and 26%, respectively, while the non-administered responder group's were 17 and 8%. These differences are statistically significant. An improvement in the treatment results with combined use of appropriate immune-modulating drugs is anticipated in the future. When clinical trials of the efficacy of these drugs are conducted, the agents should be given tothe patients with satisfactory tumor regression after RT, although they still take much time and cost.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 17:49:10